Table 1.
Patient and tumor characteristics for 1,431high risk, non-metastatic melanoma patients.
(key: nodal characteristic: Clin(−)/Path(−)/#(0) = no clinically evident lymphadenopathy, no pathologic lymph node metastases. Clin(−)/Path(+)/#(≥1) = no clinically evident lymphadenopathy, positive pathologic lymph node metastases. Clin(−)/Path(+)/#(≥1) = clinically evident lymphadenopathy, positive pathologic lymph node metastases.)
| Total Cohort | Neutrophil-to-Lymphocyte Ratio | p-value | ||
|---|---|---|---|---|
| < 3 | ≥ 3 | |||
| (n = 1,431) | (n = 847) | (n = 584) | ||
| Age (years), median (range) | 63.4 (4 – 99.6) | 60.2 (4 – 99.6) | 67.35 (16.3 – 95.5) | <0.001 |
| Sex | ||||
| Female | 550 (38.4%) | 375 (44.3%) | 175 (30%) | <0.001 |
| Male | 881 (61.6%) | 472 (55.7%) | 409 (70%) | |
| Tumor Site | ||||
| Extremity | 534 (37.3%) | 322 (38%) | 212 (36.3%) | 0.275 |
| Hand/Foot | 172 (12%) | 111 (13.1%) | 61 (10.4%) | |
| Head/Neck | 332 (23.2%) | 193 (22.8%) | 139 (23.8%) | |
| Trunk | 393 (27.5%) | 221 (26.1%) | 172 (29.5%) | |
| Tumor Thickness (mm) | ||||
| N/A* | 56 | 29 | 27 | |
| 0 – 1 | 102 (7.4%) | 63 (7.7%) | 39 (7%) | 0.004 |
| 1.1 – 2 | 302 (22%) | 196 (24%) | 106 (19%) | |
| 2.1 – 4 | 545 (39.6%) | 335 (41%) | 210 (37.7%) | |
| >4 | 426 (31%) | 224 (27.4%) | 202 (36.3%) | |
| Mitotic index, median(range) | 4 (0 – 58) | 3 (0 – 58) | 4 (0 – 36) | <0.001 |
| Ulceration | ||||
| Identified | 631 (44.1%) | 361 (42.6%) | 270 (46.2%) | 0.194Ɨ |
| Not identified | 798 (55.8%) | 485 (57.3%) | 313 (53.6%) | |
| Unknown | 2 (0.1%) | 1 (0.1%) | 1 (0.2%) | |
| TILs | ||||
| Identified | 649 (45.4%) | 393 (46.4%) | 256 (43.8%) | 0.366Ɨ |
| Not identified | 780 (54.5%) | 453 (53.5%) | 327 (56%) | |
| Unknown | 2 (0.1%) | 1 (0.1%) | 1 (0.2%) | |
| LVI | ||||
| Identified | 220 (15.4%) | 122 (14.4%) | 98 (16.8%) | 0.250Ɨ |
| Not identified | 1209 (84.5%) | 724 (85.5%) | 485 (83%) | |
| Unknown | 2 (0.1%) | 1 (0.1%) | 1 (0.2%) | |
| In-transit status | ||||
| Negative | 1311 (91.6%) | 783 (92.4%) | 528 (90.4%) | 0.205 |
| Positive | 120 (8.4%) | 64 (7.6%) | 56 (9.6%) | |
| N substage | ||||
| N0 | 726 (50.7%) | 439 (51.8%) | 287 (49.1%) | 0.034 |
| N1a | 264 (18.4%) | 165 (19.5%) | 99 (17%) | |
| N1b | 103 (7.2%) | 65 (7.7%) | 38 (6.5%) | |
| N2a | 64 (4.5%) | 40 (4.7%) | 24 (4.1%) | |
| N2b | 70 (4.9%) | 30 (3.5%) | 40 (6.8%) | |
| N2c | 64 (4.5%) | 34 (4%) | 30 (5.1%) | |
| N3 | 140 (9.8%) | 74 (8.7%) | 66 (11.3%) | |
| Nodal Characteristic | ||||
| Clin(−)/Path(−)/#(0) | 808 (56.5%) | 481 (56.8%) | 327 (56%) | 0.169 |
| Clin(−)/Path(+)/#(≥1) | 456 (31.9%) | 278 (32.8%) | 178 (30.5%) | |
| Clin(+)/Path(+)/#(≥1) | 167 (11.7%) | 88 (10.4%) | 79 (13.5%) | |
Ɨ
p value was from the test combining unknown and not identified.
*
N/A was not included in the test.